158 related articles for article (PubMed ID: 35580321)
21. A comprehensive analysis of coagulopathy during anti-B cell maturation antigen chimeric antigen receptor-T therapy in multiple myeloma, a retrospective study based on LEGEND-2.
Liu R; Lv Y; Hong F; Zhao W; Lei B; Liu J; Zhang W; He A; Wang F
Hematol Oncol; 2023 Oct; 41(4):704-717. PubMed ID: 37186314
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma.
Goto H; Makita S; Kato K; Tokushige K; Fujita T; Akashi K; Izutsu K; Teshima T
Int J Clin Oncol; 2020 Sep; 25(9):1736-1743. PubMed ID: 32448949
[TBL] [Abstract][Full Text] [Related]
24. Health Care Resource Utilization and Total Costs of Care Among Patients with Diffuse Large B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy in the United States.
Keating SJ; Gu T; Jun MP; McBride A
Transplant Cell Ther; 2022 Jul; 28(7):404.e1-404.e6. PubMed ID: 35354101
[TBL] [Abstract][Full Text] [Related]
25. [Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma].
Xiao X; Jiang YY; Cao YQ; Li Q; Jin X; Meng JX; Sui T; Li YM; Zhao MF
Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):276-280. PubMed ID: 31104437
[No Abstract] [Full Text] [Related]
26. Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review.
Du J; Zhang Y
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1575-1582. PubMed ID: 32222815
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan.
Goto H; Kitawaki T; Fujii N; Kato K; Onishi Y; Fukuhara N; Yamauchi T; Toratani K; Kobayashi H; Yoshida S; Shimo M; Onodera K; Senjo H; Onozawa M; Hirata K; Yokota I; Teshima T
Int J Clin Oncol; 2023 Jun; 28(6):816-826. PubMed ID: 37071252
[TBL] [Abstract][Full Text] [Related]
28. Dual specific CD19/CD22-targeted chimeric antigen receptor T-cell therapy for refractory diffuse large B-cell lymphoma: A case report.
Huang C; Zhang HC; Ho JY; Liu RX; Wang L; Kuang N; Zheng MR; Liu LH; Li JQ
Oncol Lett; 2020 Oct; 20(4):21. PubMed ID: 32774494
[TBL] [Abstract][Full Text] [Related]
29. Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy.
Jiang H; Liu L; Guo T; Wu Y; Ai L; Deng J; Dong J; Mei H; Hu Y
Ann Hematol; 2019 Jul; 98(7):1721-1732. PubMed ID: 31055613
[TBL] [Abstract][Full Text] [Related]
30. Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital's perspective.
Yang H; Hao Y; Chai X; Qi CZ; Wu EQ
J Med Econ; 2020 Sep; 23(9):1016-1024. PubMed ID: 32397772
[No Abstract] [Full Text] [Related]
31. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
Front Immunol; 2021; 12():611366. PubMed ID: 33708205
[TBL] [Abstract][Full Text] [Related]
32. [Medium-term follow-up of patients treated with chimeric antigen receptor T cells (CAR T cells): Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Alsuliman T; Drieu La Rochelle L; Campidelli A; Duléry R; Fayard A; Mamez AC; Mear JB; Schneider PO; Trevet A; Vicente C; Yakoub-Agha I
Bull Cancer; 2021 Dec; 108(12S):S65-S71. PubMed ID: 33678408
[TBL] [Abstract][Full Text] [Related]
33. [Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Jiang YL; Li Q; Pu YD; Jiang YY; Yuan T; Deng Q; Li YM; Han MZ; Zhai WH
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):495-501. PubMed ID: 32654464
[No Abstract] [Full Text] [Related]
34. Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma in Chinese patients.
Fan L; Wang L; Cao L; Zhu H; Xu W; Li J
Front Med; 2022 Apr; 16(2):285-294. PubMed ID: 34727319
[TBL] [Abstract][Full Text] [Related]
35. Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma.
Sang W; Wang X; Geng H; Li T; Li D; Zhang B; Zhou Y; Song X; Sun C; Yan D; Li D; Li Z; Li C; Xu K
Front Immunol; 2022; 13():858021. PubMed ID: 35432352
[TBL] [Abstract][Full Text] [Related]
36. A potential role of preexisting inflammation in the development of acute myelopathy following CAR T-cell therapy for diffuse large B-cell lymphoma.
Beauvais D; Cozzani A; Blaise AS; Moreau AS; Varlet P; Gaggero S; Alidjinou EK; Vannod-Michel Q; Morschhauser F; Labalette M; Yakoub-Agha I; Mitra S
Curr Res Transl Med; 2022 May; 70(2):103331. PubMed ID: 34999480
[TBL] [Abstract][Full Text] [Related]
37. The promise of CAR T-cell therapy in aggressive B-cell lymphoma.
Nair R; Neelapu SS
Best Pract Res Clin Haematol; 2018 Sep; 31(3):293-298. PubMed ID: 30213399
[TBL] [Abstract][Full Text] [Related]
38. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.
Hay KA; Hanafi LA; Li D; Gust J; Liles WC; Wurfel MM; López JA; Chen J; Chung D; Harju-Baker S; Cherian S; Chen X; Riddell SR; Maloney DG; Turtle CJ
Blood; 2017 Nov; 130(21):2295-2306. PubMed ID: 28924019
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of CD19 chimeric antigen receptor T cells in the treatment of 11 patients with relapsed/refractory B-cell lymphoma: a single-center study.
Huang C; Wu L; Liu R; Li W; Li Z; Li J; Liu L; Shan B
Ann Transl Med; 2020 Sep; 8(17):1048. PubMed ID: 33145267
[TBL] [Abstract][Full Text] [Related]
40. Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion.
Bishop MR; Maziarz RT; Waller EK; Jäger U; Westin JR; McGuirk JP; Fleury I; Holte H; Borchmann P; Del Corral C; Tiwari R; Anak Ö; Awasthi R; Pacaud L; Romanov VV; Schuster SJ
Blood Adv; 2019 Jul; 3(14):2230-2236. PubMed ID: 31332046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]